Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Vitamin D3

Cholecalciferol · Fat-Soluble Hormone-Vitamin

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Two separate evidence grades apply. For treating and preventing vitamin D deficiency disease, the case is overwhelming and reaches grade 5: cholecalciferol reverses nutritional rickets in children and osteomalacia in adults, a relationship established across a century of clinical work and reflected in every national guideline (NIH ODS, StatPearls). For broad primary prevention in already-replete adults, the evidence sits near grade 2 and is largely null. The VITAL trial (Manson et al., NEJM 2019, 25,871 adults, 2,000 IU/day) found no reduction in major cardiovascular events or cancer incidence versus placebo. Its bone-health ancillary (LeBoff et al., NEJM 2022) found no reduction in total fractures (HR 0.98, 95% CI 0.89 to 1.08) or hip fractures (HR 1.01, 95% CI 0.70 to 1.47), with no benefit even in participants with low baseline levels. The USPSTF (2024) recommends against supplementation to prevent falls or fractures in community-dwelling adults. The headline grade 5 attaches to correcting deficiency, not to the megadose-for-everyone narrative.

FDA
Legal supplement (DSHEA)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Safe at recommended doses; the genuine hazard is chronic megadosing, which can cause hypercalcemia and kidney harm, so periodic 25-hydroxyvitamin D testing beats guessing.

Vitamin D3, or cholecalciferol, is the form the human body makes in skin exposed to sunlight, and it is among the most-studied supplements in existence. The evidence splits cleanly. For people who are genuinely deficient, it is foundational and corrects rickets in children and osteomalacia in adults. For already-replete adults hoping to prevent heart disease, cancer, or fractures, the large VITAL trial and the USPSTF found essentially no benefit. The sensible goal is to be replete, confirmed by a blood test, rather than to chase high numbers with megadoses.

The most-tested supplement on Earth, strongest in deficiency, modest in replete adults.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Treating and preventing vitamin D deficiency, including rickets and osteomalacia
  • Correcting low 25-hydroxyvitamin D confirmed by blood test
  • Bone health in deficient or at-risk populations
  • Pregnancy and lactation supplementation per obstetric guidance
  • Supporting groups at high deficiency risk (limited sun, darker skin, obesity, malabsorption, older adults)
  • Modest, inconsistent signal for acute respiratory infection prevention

How it works

Cholecalciferol from skin synthesis or supplementation is hydroxylated in the liver to 25-hydroxyvitamin D (the storage form, measured on blood tests) and again in the kidney to 1,25-dihydroxyvitamin D (the active hormone). The active form binds the vitamin D receptor expressed in nearly every tissue, regulating roughly two hundred genes involved in calcium homeostasis, immune modulation, and cellular differentiation. The mechanism is the closest a "vitamin" gets to being a steroid hormone.

How it is taken

Take with the fattiest meal of the day, vitamin D3 is fat-soluble and absorption can vary by two-to-three-fold based on meal composition. Daily dosing meaningfully outperforms weekly or monthly bolus protocols for falls prevention and most other endpoints; the older megadose practice has largely been superseded. The right dose depends on starting status: deficient individuals (<30 ng/mL) typically need 2000-5000 IU/day for several months to replete; maintenance once replete is typically 1000-2000 IU/day. Annual or biannual 25-OH-D blood testing is straightforward, inexpensive, and the right way to guide individual dosing. Magnesium status matters, vitamin D activation enzymes require magnesium as cofactor, and magnesium-deficient users genuinely respond less to D3 supplementation.

Maintenance
1000-2000 IU/day with fatty meal
Repletion (deficient)
2000-5000 IU/day for 8-12 weeks, then maintenance
Older adults
800-1000 IU/day daily for falls prevention, daily, not monthly
Pregnancy
1000-2000 IU/day; coordinate with OB-GYN
Pediatric
400-1000 IU/day under pediatric guidance
Food state
With fatty meal, non-negotiable for adequate absorption
Blood test
25-OH-D annually or biannually; target 30-50 ng/mL most guidelines
Bolus dosing
Generally avoid; daily is more effective and safer

Which form to buy

Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.

  • Cholecalciferol (D3), Oil-Based Softgel

    Rating: gold

    The most-studied and best-absorbed form. D3 is the form skin synthesizes from UV exposure and the form supplemented in nearly all major trials. Oil-based softgels meaningfully outperform dry tablets in raising 25-OH-D blood levels because of the fat-soluble pharmacokinetics. Most premium brands use this format.

  • D3 + K2 (MK-7) Combination

    Rating: gold

    Co-formulated D3 with menaquinone-7, addresses the calcium-distribution question (K2 directs calcium toward bone and away from arteries). Mechanistically supportive, particularly at higher D3 doses. Common in bone-health protocols. Doses typically 2000-5000 IU D3 + 90-180mcg MK-7.

  • D3 + Magnesium + K2 Triple Stack

    Rating: gold

    Premium formulation acknowledging that magnesium is the cofactor for vitamin D activation (25-hydroxylation and 1-alpha-hydroxylation). Magnesium-deficient users genuinely respond less to D3 supplementation. The triple stack is mechanistically sound rather than marketing-driven.

  • D3 Liquid Drops

    Rating: good

    Useful for pediatric dosing (precise titration), users with swallowing difficulty, and high-dose protocols where pill count becomes inconvenient. Typically dispensed in MCT oil or similar fat carrier. Effective and well-absorbed.

  • Ergocalciferol (D2), Prescription

    Rating: caution

    Plant-derived (yeast-irradiated). Used in prescription 50,000 IU weekly bolus protocols (Drisdol) for diagnosed deficiency. Head-to-head comparisons (Heaney, Tripkovic) show D2 less effective per IU than D3 for raising and maintaining blood levels, and D2 may shorten the half-life of co-circulating D3. Mostly outdated outside specific prescription contexts.

  • D3 Sublingual Spray

    Rating: caution

    Marketed for "superior absorption" via oral mucosa. Independent evidence is thin; some pharmacokinetic studies suggest equivalence to oral, others suggest inferior. The marketing premium typically exceeds documented benefit. Reasonable backup if GI absorption is genuinely compromised.

  • High-Dose Bolus (50,000+ IU monthly)

    Rating: caution

    Older clinical protocol for severe deficiency. Sanders 2010 trial in older women found 500,000 IU annual bolus actually increased fall and fracture risk versus placebo. Daily moderate dosing has substantially better safety than infrequent megadoses. Reserve for specific clinical situations with monitoring.

Who it works for, and who it does not

  • Documented deficiency (<30 ng/mL 25-OH-D)

    Strength of evidence for this group: strong

    The clearest case. Repletion to >30 ng/mL meaningfully improves bone, immune, and falls outcomes in deficient populations. The Endocrine Society and most clinical guidelines align on supplementation in this cohort. Effect sizes largest where baseline is lowest.

  • Older adults at fall risk

    Strength of evidence for this group: strong

    Bischoff-Ferrari meta-analyses consistently show 800-1000 IU/day reduces falls in adults over 65, particularly those starting below 30 ng/mL. Among the most reproducible vitamin D benefits across trials. Daily dosing meaningfully outperforms infrequent megadoses for this endpoint.

  • Pregnancy and lactation

    Strength of evidence for this group: modest

    Maternal D3 supplementation supports fetal skeletal development and improves infant 25-OH-D status. Standard prenatal vitamins provide 400-800 IU; clinical recommendations have moved toward 1000-2000 IU for many pregnancies. Coordinate with OB-GYN given evolving guidance.

  • Skin-shielded populations (dark skin, fully covered, indoor)

    Strength of evidence for this group: strong

    Skin melanin meaningfully reduces UV-driven D3 synthesis. South Asian, African, and Middle Eastern populations at northern latitudes have substantially elevated deficiency rates even in summer. Fully-covered traditional dress and indoor lifestyle compound the effect.

  • Autoimmune disease (MS, lupus, RA)

    Strength of evidence for this group: cautious

    Observational data consistently shows lower 25-OH-D in autoimmune populations; whether supplementation modifies disease course is more contested. Some trials (Fitzgerald MS) show modest benefit; others null. Reasonable adjunct to standard rheumatology/neurology care, not substitute.

  • Already-replete adults (>40 ng/mL)

    Strength of evidence for this group: weak

    The VITAL trial enrolled adults already largely replete and nulled the primary cardiovascular and cancer endpoints. Effect of additional supplementation in this cohort is modest at best for non-skeletal endpoints. Maintenance dosing makes sense; aggressive higher dosing in this group is harder to defend.

  • Cystic fibrosis, fat malabsorption

    Strength of evidence for this group: cautious

    D3 is fat-soluble; absorption is compromised in CF, biliary disease, gastric bypass, and inflammatory bowel disease. Standard oral doses may be inadequate; high-dose protocols or 25-OH-D (calcifediol) supplementation may be needed. Specialist guidance required.

Taken with other things

Combinations people actually use. Evidence for one ingredient is not evidence for a pair.

  • Vitamin K2 (MK-7)

    Interaction: synergy

    Mechanistically supportive, K2 directs calcium toward bone matrix and away from arterial walls, addressing the theoretical concern about calcium maldistribution at higher D3 doses. Bone-health protocols increasingly include both. Particularly worth pairing at D3 doses above 2000 IU/day.

  • Magnesium

    Interaction: synergy

    Real cofactor relationship. Magnesium is required for both 25-hydroxylase and 1-alpha-hydroxylase, the enzymes that activate vitamin D to its active hormonal form. Magnesium-deficient users genuinely respond less to D3 supplementation. Co-supplementation is mechanistically defensible, not marketing.

  • Calcium

    Interaction: synergy

    The Tang 2007 meta-analysis showed fracture prevention required co-supplementation of calcium with D3; D3 alone was substantially less effective for this endpoint. Dietary calcium is preferred when possible; supplementation when documented insufficiency.

  • Boron

    Interaction: synergy

    Modest cofactor for vitamin D metabolism. Bone-health stacks sometimes include 3-6mg boron alongside D3/K2/magnesium/calcium. Marginal benefit; not essential.

  • Vitamin A (retinol)

    Interaction: caution

    At very high doses, vitamin A may antagonize vitamin D receptor activity. Cod liver oil, a traditional vitamin D source, also delivers significant vitamin A. Practical concern only at chronic megadose vitamin A intake.

  • Thiazide diuretics

    Interaction: caution

    Thiazides reduce urinary calcium excretion. Combined with D3 supplementation, this can elevate serum calcium. Monitor in users on hydrochlorothiazide or similar.

  • Sarcoidosis and granulomatous disease

    Interaction: avoid

    These conditions produce active 1,25-D autonomously through inflammatory tissue. Standard D3 supplementation can cause hypercalcemia in these patients. Specialist-guided dosing only.

  • Sun exposure

    Interaction: synergy

    Skin D3 synthesis remains the natural baseline. Moderate non-burning sun exposure complements oral supplementation. Sunscreen blocks D3 synthesis; population trends toward indoor lifestyles and sunscreen use are the underlying drivers of the modern deficiency increase.

What to look for on the label

Look for: D3 (cholecalciferol) specifically, not D2; oil-based softgel for fat-soluble absorption; third-party verification (NSF, USP, ConsumerLab); 25-OH-D testing to guide individual dose; K2 (MK-7) and/or magnesium co-formulation at doses above 2000 IU. Avoid: D2 (ergocalciferol) outside prescription contexts; dry tablets in users who don't consistently take with fat; "high-dose monthly bolus" protocols outside specific clinical contexts; products that obscure the IU dose in proprietary blends.

Safety in detail

  • Toxicity is real but rare in conventional supplementation. Chronic intake above 10,000 IU/day can produce hypercalcemia, kidney stones, and soft-tissue calcification.
  • The 25-OH-D blood test is the right way to guide dosing. Target range is debated: most labs flag below 30 ng/mL as insufficient; some experts argue 40-60 ng/mL is preferable for non-skeletal effects.
  • Sarcoidosis and granulomatous diseases produce 1,25-D autonomously, supplementation in these conditions can cause hypercalcemia at conventional doses.
  • Fat-soluble nature means it accumulates; large boluses (50,000 IU monthly) are not equivalent to daily dosing and have produced fall-and-fracture signals in older adults.

What people get wrong

  • Often saidHigher vitamin D levels are always better.

    ActuallyAbove roughly 40-60 ng/mL, additional benefit is not demonstrated, and toxicity risk rises at chronic high doses. Aim to be replete, not high.

  • Often saidVitamin D prevents COVID.

    ActuallyThe pandemic-era enthusiasm was understandable but the randomized trials have been mixed. Deficiency correction is reasonable; mega-dosing as prevention is not supported.

  • Often saidYou can get enough from sun alone.

    ActuallyIn most non-equatorial latitudes for most of the year, skin synthesis is inadequate to maintain 30+ ng/mL year-round, particularly above age forty.

Who profits, and who pushes back

  • Michael Holick

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itBoston University · longtime advocate

    Long-standing public advocate of higher target levels (40-60 ng/mL). Has had financial relationships with vitamin D testing labs and tanning-industry sources, disclosed but worth knowing.

  • Endocrine Society

    Promotes itClinical guideline body

    Recommends supplementation to maintain 25-OH-D above 30 ng/mL in adults at risk, with screening of at-risk populations.

  • JoAnn Manson

    Promotes itHarvard / VITAL principal investigator

    Independent academic voice. VITAL trial results have shaped a more cautious mainstream stance on supplementation in already-replete adults.

  • Cliff Rosen

    Pushes backBone metabolism researcher · IOM panel member

    The evidence for non-skeletal benefits in already-replete adults has not materialized in the large randomized trials. We should be careful not to oversell what the data actually show.

How we got here

Discovered in 1922 by Elmer McCollum during the rickets era, childhood rickets was endemic in industrial-revolution Northern Europe and US cities until milk fortification began in the 1930s. The vitamin/hormone distinction emerged in the 1970s as the activation pathway was characterized. Population-wide deficiency concerns re-emerged in the 2000s with widespread sunscreen use, indoor lifestyles, and modern dietary patterns.

  1. 1922McCollum identifies vitamin D
  2. 1930sUS milk fortification begins, ending epidemic childhood rickets
  3. 1971DeLuca characterizes the activation pathway to 1,25-D
  4. 2010IOM raises RDA to 600-800 IU/day, more conservative than some advocates wanted
  5. 2019VITAL trial nulls primary endpoints
  6. 2022D-Health trial confirms null on mortality

What we do not know

  • Whether non-skeletal effects (cardiovascular, autoimmune, cancer) translate at population scale or require deficiency to demonstrate benefit.
  • Optimal target range for the 25-OH-D blood level (30 vs 40 vs 50 ng/mL).
  • Whether genetic variation in the vitamin D receptor explains some of the inconsistency in trials.
  • Whether vitamin K2 co-supplementation meaningfully changes the long-term safety and calcium-distribution picture.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

D3 (cholecalciferol, animal-source typically from lanolin) is the dominant supplemental form and the form produced by skin synthesis. D2 (ergocalciferol, plant-source) is less effective at raising blood levels and is now uncommon outside prescription contexts. Quality is generally high across the category; oil-based softgels absorb better than dry tablets for most users.

At a glance

Active form
1,25-dihydroxyvitamin D (calcitriol)
Storage form measured
25-hydroxyvitamin D
Typical maintenance dose
1000-4000 IU/day
Insufficiency threshold
<30 ng/mL (most labs)
Toxicity threshold
Chronic >10,000 IU/day
Best testing
25-OH-D, annually or biannually

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Vitamin D3. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources

The studies that matter

  • VITAL2019

    Twenty-five-thousand-person randomized trial of 2000 IU/day in adults already largely replete, null on primary cardiovascular and cancer endpoints; positive secondary signals on cancer mortality and autoimmune incidence.

  • D-Health Trial2022

    Twenty-one-thousand Australian adults: null on overall mortality; no significant cardiovascular benefit.

  • Bischoff-Ferrari falls meta-analyses2009-2020

    Falls prevention in older adults at 800-1000 IU/day, modest but reproducible benefit, particularly in those starting below 30 ng/mL.

  • Martineau respiratory infection meta-analysis2017

    Prevention of acute respiratory infections, larger effect in deficient subgroups; smaller absolute effect in already-replete adults.